(154 days)
Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, intermittent infusion, continuous infusion or aspiration. This set may be used with power injector procedures to a maximum pressure of 325 psi at a flow rate of 10ml per second. Non Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, intermittent infusion, continuous infusion or aspiration.
Sterile, single use non-pyrogenic intravenous administration extension set comprised of 7 inch tubing bonded to a male luer on one end and a female luer on the other end with a clamp in between. A swabable, needle-free port is connected to the female luer. This device is not made with the plasticizer Diethylhexylphthalate (DEHP).
The provided text describes information for the Q2® Low Pressure Power Injection Extension Set, which is a medical device, and does not contain information about an AI/ML powered device. Therefore, I cannot extract information pertaining to AI/ML acceptance criteria or studies.
However, I can provide available information regarding the device's performance as described in the document in a table format:
1. A table of acceptance criteria and the reported device performance
| Test Parameter | Acceptance Criteria / Predicate Performance | Reported Device Performance (Q2 Low Pressure Power Injection Extension Set) |
|---|---|---|
| Particulate Testing | Per ISO 8536-4:2010 | Successfully demonstrated device performs as intended and meets manufacturer specification. |
| Simulated Shipping | (Not explicitly stated but implied to meet functional requirements) | Successfully demonstrated device performs as intended and meets manufacturer specification. |
| Package Burst | (Not explicitly stated but implied to meet functional requirements) | Successfully demonstrated device performs as intended and meets manufacturer specification. |
| Priming Volume | Predicate: < 1 mL | 1.0 mL |
| Backpressure Leak | (Not explicitly stated but implied to meet functional requirements) | Successfully demonstrated device performs as intended and meets manufacturer specification. |
| Flow Rate | Maximum pressure of 325 psi at a flow rate of 10 mL per second | Successfully demonstrated device performs as intended and meets manufacturer specification. Meets 325 psi at 10 mL/second. |
| Simulated Maximum Use | (Not explicitly stated but implied to meet functional requirements) | Successfully demonstrated device performs as intended and meets manufacturer specification. |
| Sterilization (Method) | Predicate: Irradiation; E-Beam | 100% EtO (Ethylene Oxide) |
| Sterilization (Minimum SAL) | Predicate: 1 x 10^-6 | 1 x 10^-6 |
| Ethylene Oxide Residuals | Per ISO 10993-7:2008 | Tested and met established guidelines. |
| Shelf Life | Predicate: 5 year | 1 year (qualified) |
| Biocompatibility | Per ISO 10993-1:2009 (Hemocompatibility, Cytotoxicity, Sensitization, Irritation/Intracutaneous Reactivity, Systemic Toxicity, Subchronic Toxicity, Material-mediated Pyrogenicity) | Test results successfully verified materials are biocompatible for clinical application. |
| Pyrogen (Bacterial Endotoxins) | Established guidelines (via LAL method) | Materials do not introduce a level of endotoxin that exceed established guidelines. |
| Pressure Rating | Max pressure of 325 psi at a flow rate of 10 mL per second | Use with low pressure power injectors up to 325 psi and maximum flow rate of 10 mL/second. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document does not specify the exact sample sizes used for each benchmark test. It only states that functional performance testing was "completed." No information is provided regarding the country of origin of the data, nor whether the tests were retrospective or prospective. These are bench tests, not clinical studies involving patient data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This section is not applicable as the device is a physical medical device (extension set) and the studies described are bench tests for functional performance, sterilization, shelf life, and biocompatibility, not studies requiring expert interpretation or ground truth establishment in the context of diagnostic or prognostic performance.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This is not applicable for the type of bench testing described in the document.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This is not applicable as the device is an intravascular administration set and not an AI/ML-powered diagnostic or assistive tool.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
This is not applicable as the device is a physical medical device and not an algorithm.
7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)
This is not applicable for the type of bench testing described. The "ground truth" for the bench tests would be defined specifications, industry standards (e.g., ISO standards), and manufacturer's established criteria for performance (e.g., maximum pressure, flow rate, SAL).
8. The sample size for the training set
This is not applicable as the device is a physical medical device and does not involve AI/ML requiring a training set.
9. How the ground truth for the training set was established
This is not applicable as the device is a physical medical device and does not involve AI/ML requiring a training set.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines representing hair or clothing.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 8, 2017
Quest Medical, Inc. Amy Clendening-Wheeler Senior Regulatory Affairs Specialist One Allentown Parkway Allen, TX 75002
Re: K162804
Trade/Device Name: Q2® Low Pressure Power Injection Extension Set Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Sets Regulatory Class: Class II Product Code: FPA Dated: February 3, 2017 Received: February 6, 2017
Dear Amy Clendening-Wheeler:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
{1}------------------------------------------------
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K162804
Device Name
Q2 Low Pressure Power Injection Extension Set
Indications for Use (Describe)
Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, infusion, continuous infusion or aspiration. This set may be used with power injector procedures to a maximum pressure of 325 psi at a flow rate of 10ml per second. Non Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, intermittent infusion, continuous infusion or aspiration.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) SUMMARY K162804
| DATE PREPARED: | March 8, 2017 | |
|---|---|---|
| SUBMITTER: | Quest Medical, Inc.One Allentown ParkwayAllen, TX 75002 USA972-390-9800/800-627-0226 | |
| Contact: Amy Clendening-WheelerPhone: (972) 332-6228Fax: (469) 795-2338Email: awheeler@questmedical.com | ||
| DEVICE NAME: | Q2® Low Pressure Power Injection Extension Set | |
| COMMON NAME: | IV Extension Sets | |
| CLASSIFICATION NAME: | Intravascular Administration Sets | |
| PRODUCT CODE: | FPA | |
| REGULATION: | 880.5440 | |
| CLASS: | II | |
| PREDICATE DEVICE: | Carefusion MaxPlus® Pressure Rated Extension Set with removable clearneedleless connector (K140831) | |
| REFERENCE DEVICE: | Quest Medical Inc. Q2® Multiport IV Administration Sets and ExtensionSets and CheckMate® IV Administration Sets and Extension Sets(K162304) | |
| DESCRIPTION: | Sterile, single use non-pyrogenic intravenous administration extensionset comprised of 7 inch tubing bonded to a male luer on one end and afemale luer on the other end with a clamp in between. A swabable,needle-free port is connected to the female luer. This device is notmade with the plasticizer Diethylhexylphthalate (DEHP). | |
| INTENDED USE: | For administration of intravenous fluids to a patient's vascular systemutilizing needle-free components and provide short-term intravascularor subcutaneous access using a variety of infusates (i.e. anesthesia |
{4}------------------------------------------------
drugs, chemotherapeutics, drugs, antibiotics, blood products, commonly used prep solutions). The device may also be used with low pressure power injectors rated for a maximum setting of 325 psi.
INDICATIONS FOR USE: Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, intermittent infusion, continuous infusion or aspiration. This set may be used with power injector procedures to a maximum pressure of 325 psi at a flow rate of 10ml per second.
Non Pressure Rated: The Q2 Low Pressure Power Injector Extension Set with needleless connector is for single use only. The extension set may be used for direct injection, intermittent infusion, continuous infusion or aspiration.
SUBSTANTIAL EQUIVALENCE
Bench Testinq
Functional performance testing including particulate testing per ISO 8536-4:2010, simulated shipping, package burst, priming volume, backpressure leak and flow rate for both normal and low pressure power injection use, and simulated maximum use for both normal and low pressure power injection use was completed for the proposed Q2 Low Pressure Power Injector Extension Set to demonstrate the device performs as intended and to manufacturer specification. Results of testing successfully demonstrate that the Q2 Low Pressure Power Injector Extension Set performs similarly to the predicate device to meet the functional requirements for both non-pressure use and low pressure power injection.
Sterilization
There is no change to the sterilization process for the proposed new Q2 Low Pressure Power Injection Extension Set from the other Quest Medical, Inc. IV Administration and Extension Set product family. The sterilization process is validated per ISO 11135 and Ethylene Oxide residuals testing was performed for the product line per ISO 10993-7:2008 "Biological Evaluation of Medical Devices – Part 7: Ethylene Oxide Sterilization Residuals." Although the method of sterilization is different from the predicate device, both devices are sterile, non-pyrogenic, single-use devices with a minimum 10 ° SAL.
Shelf Life
Shelf life for the Q2 Low Pressure Power Injection Set is qualified to 1 year. The predicate device is qualified to 5 years shelf life. The difference in shelf life is not a significant
{5}------------------------------------------------
difference as this attribute has no impact to the function of the device. The shelf life of each device is validated to meet each manufacturer's specification.
Biocompatibility
The materials of construction for the Model 95714 are identical to that of the Quest Medical Inc. Reference Devices of K162304, where the fully assembled representative IV Administration Set was tested according to ISO 10993-1:2009. Hemocompatibility, Cytotoxicity, Sensitization, Irritation/Intracutaneous Reactivity, Systemic Toxicity, Subchronic Toxicity, and Materialmediated Pyrogenicity tests were performed. Test results successfully verified that the IV Administration Set and Extension Set materials of construction are biocompatible for their clinical application.
Pyrogen
Pyrogen testing for bacterial endotoxins was performed via the kinetic chromogenic LAL (Limulous Amebocyte Lysate) method. The results found that the proposed new materials do not introduce a level of endotoxin that exceed established guidelines.
Comparison to Predicate:
The following table shows a comparison between the Q2® Low Pressure Power Injection Extension Set subject device to the Carefusion MaxPlus Pressure Rated Extension Set with removable clear needleless connector predicate device. The subject and predicate devices are similar in physical properties, materials, and configuration.
| Predicate Device | Subject Device | |
|---|---|---|
| 510(k) | K140831 | K162804 |
| Model # | MP5303-C | 95714 |
| Brand Name | MaxPlus Pressure Rated Extension Set withremovable clear needleless connector | Q2 Low Pressure Power Injector Extension Set |
| Manufacturer | CareFusion | Quest Medical, Inc. |
| FDA RegulationNumber | 21CFR 880.5440 | SAME |
| FDA Class | II | SAME |
| FDA ProductCode | FPA | SAME |
| DeviceDescription | Intravascular extension sets intended forsingle patient use, including pediatrics andimmunocompromised patients, for directinjection, intermittent infusion, continuousinfusion or aspiration of drugs, blood, andfluids. The extension sets include aneedleless connector to allow thorough and | The device is an intravascular extension setavailable in one configuration that includes aneedleless connector. The device is not madewith the plasticizer Diethylhexylphthalate(DEHP). |
| Predicate Device | Subject Device | |
| easy disinfection due to a solid, flat, smoothsurface and eliminates the risk ofneedlestick injuries. The extension sets arenot made from natural rubber latex orDEHP. Configurations are available withneedleless connectors, split septum ports,filters, stopcocks, manifolds, and/or T-connectors. | ||
| Intended Use | For direct injection, intermittent infusion,continuous infusion or aspiration. | For administration of intravenous fluids to apatient's vascular system utilizing needle-freecomponents and provide short-termintravascular or subcutaneous access using avariety of infusates (i.e. anesthesia drugs,chemotherapeutics, drugs, antibiotics, bloodproducts, commonly used prep solutions). Thedevice may also be used with low pressurepower injectors rated for a maximum settingof 325 psi. |
| Indications forUse | Pressure Rated: The MaxZero multi fuseextension set with needleless connector(s) isfor single use only. The extension set may beused for direct injection, intermittentinfusion, continuous infusion or aspiration.This set may be used with power injectorprocedures to a maximum pressure of 325psi at a flow rate of 10ml per second.Non Pressure Rated: The MaxZero multifuse extension set with needlelessconnector(s) is for single use only. Theextension set may be used for directinjection, intermittent infusion, continuousinfusion or aspiration. | Pressure Rated: The Q2 Low Pressure PowerInjector Extension Set with needlelessconnector is for single use only. The extensionset may be used for direct injection,intermittent infusion, continuous infusion oraspiration. This set may be used with powerinjector procedures to a maximum pressure of325 psi at a flow rate of 10ml per second.Non Pressure Rated: The Q2 Low PressurePower Injector Extension Set with needlelessconnector is for single use only. The extensionset may be used for direct injection,intermittent infusion, continuous infusion oraspiration.(SAME) |
| Device Design | ||
| Components | Tubing, Luer, Check valve, NeedlelessConnector, Male spin lock connectorNon-fluid contacting: Pinch clamp, ventedfemale luer lock cap | SAME |
| Dimensions | Length: 7 inch (18cm) | SAME |
| DeviceMaterials | ||
| Tubing | PVC- Purple striped, non-DEHP, standardbore | Identical to Quest Medical, Inc. ReferenceDevice K162304: PVC - clear, non-DEHP AlphaGary 2235L-80, standard bore |
| Luer | Co-Polyester | Identical to Quest Medical, Inc. Reference |
| Predicate Device | Subject Device | |
| NeedlelessConnector | MaxZero Clear- Polycarbonate/silicone | Device K162304: Co-polyesterIdentical to Quest Medical, Inc. ReferenceDevice K162304: SwabSite Valve –Polycarbonate/silicone |
| Male spin luerlock/hub | ABS thermoplastic | Identical to Quest Medical, Inc. ReferenceDevice K162304: CYRO XT 250-301 |
| Technology | ||
| Use | Use with low pressure power injectors up to325 psi and maximum flow rate of 10mL/second | SAME |
| Priming volume | < 1 mL | 1.0 mL |
| Energy Source | User Operated | SAME |
| Principle ofOperation | Luer activation; direct injection, intermittentinfusion, continuous infusion, aspiration | SAME |
| Sterilization andPackage | ||
| Method | Irradiation; E-Beam | 100% EtO |
| Minimum SAL | 1 x 10-6 | SAME |
| Packaging | Tyvek pouch | SAME |
| Shelf Life | 5 year | 1 year |
| Disposable orReusable | Disposable | SAME |
{6}------------------------------------------------
{7}------------------------------------------------
CONCLUSION:
Results of all functional performance testing conducted successfully demonstrate that the proposed new Q2 Low Pressure Power Injection Extension Set is substantially equivalent to the legally marketed predicate device.
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.